Skip to main content

Table 1 Description of the case population studied

From: Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study

  Gender Age Fertile Heme arginate PBG ALA GFR
F1 F 54 No No 3 1 >60
F2 F 32 Yes No 7 6 >60
F3 F 36 Yes No 10 6 >60
F4 F 37 Yes No 16 10 >60
F5 F 25 Yes No 16 13 >60
F6 F 31 Yes No 17 15 >60
M1 M 52 Yes No 19 9 >60
F7 F 49 Yes No 23 11 >60
F8 F 34 Yes No 26 21 >60
F9 F 35 Yes No 28 12 >60
F10 F 31 Yes No 29 7 >60
F11 F 35 Yes No 30 23 >60
F12 F 34 Yes No 30 12 >60
F13 F 27 Yes No 32 22 >60
F14 F 42 Yes No 32 21 52.84
F15 F 51 No No 34 31 >60
F16 F 22 Yes No 34 15 >60
F17 F 29 Yes No 35 16 >60
F18 F 41 Yes No 37 27 >60
F19 F 31 Yes No 45 20 >60
F20 F 20 Yes No 52 42 >60
M2 M 53 Yes Yes 57 41 > 60
F21 F 31 Yes Yes 63 40 >60
F22 F 41 Yes Yes 64 40 >60
  1. Heme arginate treatment: Normosang®; 3 mg/Kg; every 2–3 weeks; PBG: porphobilinogen concentrations (nmol/mmol creatinine); ALA: aminolevulinic acid concentrations nmol/mmol creatinine). GFR: glomerular filtration rate (mls/min).